Recent advances showed that CDNF is more specific for the treatment of PD; the Phase I monthly intraputamenal CDNF infusions in patients with PD using a bone-anchored transcutaneous port connected to four catheters demonstrated its safety and a favorable tolerability profile [123]. This evidence concerns the gene CDNF and Parkinson disease.